NOVAST Laboratories, Limited (SHE:301569)
China flag China · Delayed Price · Currency is CNY
18.22
+0.44 (2.47%)
Oct 30, 2026, 3:04 PM CST

NOVAST Laboratories Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1,010895.47866.22700.43550.07646.38
Revenue Growth
16.57%3.38%23.67%27.33%-14.90%14.34%
Gross Profit
588.55479.18454.87331.29269.37311.23
Operating Income
353.34244.74238.3986.6638.03108.51
Net Income
311.22227.82260.15115.7911389.61
Earnings Per Share
0.410.300.340.150.150.15
EPS Growth
20.36%-11.77%126.67%-0.00%0%-25.00%

Revenue by Segment

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '24 Dec '23 Dec '22 Dec '21
Sales of Preparations
890.9860.79694.83543.84625.61
R&D and Other Services
4.575.435.66.2320.77
Total
895.47866.22700.43550.07646.38

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash (Debt)
1,4101,1991,009808.46703.67205.06
Net Cash Growth
39.73%18.81%24.84%14.89%243.16%3.30%
Net Cash Per Share
1.861.581.331.070.930.34
Cash & Investments
1,4101,1991,009808.46703.67205.06

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
381.29322.58267.02200.91209.21166.2
Capital Expenditures
-64.73-75.3-105.86-126.96-69.79-35.8
Free Cash Flow
316.55247.28161.1673.96139.42130.4
Free Cash Flow Growth
96.42%53.44%117.92%-46.95%6.92%-7.09%

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
58.28%53.51%52.51%47.30%48.97%48.15%
Operating Margin
34.99%27.33%27.52%12.37%6.91%16.79%
Pretax Margin
35.22%29.38%33.49%19.44%23.67%16.68%
Profit Margin
30.82%25.44%30.03%16.53%20.54%13.86%
FCF Margin
31.35%27.62%18.61%10.56%25.35%20.17%